Maternal influenza infection is known to cause substantial morbidity and mortality among pregnant women and young children. Many professional healthcare bodies including the World Health Organization (WHO) have identified pregnant women as a priority risk group for receipt of inactivated seasonal influenza vaccination. However influenza prevention in this group is not yet a public health priority in India. This literature review was undertaken to examine the Indian studies of influenza among pregnant women. Eight Indian studies describing influenza burden and/or outcomes among pregnant women with influenza were identified. In most studies, influenza A (pH1N1) was associated with increased maternal mortality (25–75%), greater disease severity, and adverse fetal outcomes as compared to nonpregnant women. Surveillance for seasonal influenza infections along with higher quality prospective studies among pregnant women is needed to quantify disease burden, improve awareness among antenatal care providers, and formulate antenatal influenza vaccine policies.
Objectives To assess effectiveness of medications used in management of Alzheimer’s Disease and Related Dementias (ADRD) on cognition and activities of daily living (ADL) trajectories and to determine whether sex modifies these effects. Design Two-year (2007–2008) longitudinal study Setting Medicare enrollment and claims data linked to the Minimum Dataset 2.0 Participants 18,950 older nursing home (NH) residents with newly-diagnosed ADRD Measurements Exposures included four medication classes: anti-dementia medications (ADM), antipsychotics, antidepressants, and mood stabilizers. Outcomes included ADLs and cognition [Cognitive Performance Scale (CPS)]. Marginal structural models were employed to account for time-dependent confounding. Results The mean age was 83.6 years and 76% of the sample was female. Baseline use for ADMs, antidepressants, antipsychotics, and mood stabilizers was 15%, 40%, 13% and 3%, respectively. The mean baseline ADL and CPS scores were 16.6 and 2.1, respectively. ADM use was not associated with a change in ADLs over time but was associated with a slower CPS decline (slope difference: −0.09 points/year, 99% CI −0.14, −0.03). Antidepressant use was associated with slower declines in ADL (slope difference: −0.36 points/year, 99% CI −0.58, −0.14) and CPS (slope difference: −0.12 points/year, 99% CI −0.17, −0.08). Sex modified the effect of both antipsychotic and mood stabilizer use on ADLs; female users declined most quickly. Antipsychotic use was associated with slower CPS decline (slope difference: −0.11 points/year, 99% CI −0.17, −0.06), while mood stabilizer use had no effect. Conclusion Despite the observed statistically significant slower declines in cognition with ADMs, antidepressants, and antipsychotics, and the slower ADL decline found with antidepressants, these benefits are not likely of clinical significance.
Objectives To describe population-based use of cognitive-enhancing and psychopharmacological medications across care settings among Medicare beneficiaries with dementia. Design One-year (2008) cross-sectional study Setting Medicare administrative claims froma 5% random sample Participants 52,754 Medicare beneficiaries with dementia aged ≥65 years with continuous Medicare Parts A, B, and D coverage and alive throughout 2008. To ascertain dementia, ≥1 medical claim with a dementia ICD-9-CM code was required prior to 2008 and an additional claim was required in 2008 to confirm active disease. Measurements Use of medications commonly prescribed in managing dementia (cognitive enhancers, antidepressants, antipsychotics, and mood stabilizers) was assessed using three separate measures: 1) Annual prevalence of use; 2) Consistency of use; 3) Count of psychopharmacological medication classes. Care setting was determined using the number of months of nursing home (NH) residency: no-NH (zero months), partial-NH (1–11 months), and full-NH (12 months). Results Community-dwellers represented 41.3% of the cohort, while 42.4% and 16.3% resided partially and fully in a NH, respectively. Annual prevalence of use was 57.1% for cognitive enhancers, 56.4% for antidepressants, 34.0% for antipsychotics, and 8.8% for mood stabilizers. Cognitive enhancer use was significantly lower among those with any NH-stay [adjusted-prevalence-ratio (99% CI) partial-NH vs. no-NH 0.84 (0.83–0.86); full-NH versus no-NH0.83 (0.81–0.85)]. In contrast, those with any NH residence had significantly higher use for all psychopharmacological medication classes compared with community-dwellers. Over half the cohort had consistent medication regimens during 2008 (64.8%). The number of psychopharmacological medication classes used increased with increasing NH-stay duration. Conclusion This population-based study documents significant differences in medication use for managing dementia across care settings and substantial use of psychopharmacological medications among older adults with dementia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.